IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.
Commercialisation of cancer vulnerability test due to start Q4 2021..........completed move to far larger premises at end of Sept 21......share price driven down..........Directors and ex-Directors hold 33%.........other significant shareholders total 35%...........only 94m shares in issue.....these will be hard to get hold of once the upward move starts.
As new CEO, Jon Burrows, stated in their recent RNS: Dr Jon Burrows, CEO of Oxford BioDynamics, said: "With OBD's strong growth outlook, our move to this larger, purpose-built facility is key to the execution of our strategy. It is important in particular as we prepare for commercialization of EpiSwitch® CiRT - our Checkpoint Inhibitor Response Test for cancer - in Q4, and with respect to our recent FNIH PACT award [3]. These are linked to the immune-oncology interests of the pharma industry, which has generated significant attention, and we expect more activity from these groups.
Larus ...... any apology then?
I wouldn't normally respond to ignorant insults....but on this occasion I'll just copy part of the RNS announced on 4th Oct on ASX:
Aura Energy Limited (ASX: AEE) TRADING HALT REQUEST
In accordance with ASX Listing Rule 17.1, Aura Energy Limited (ASX: AEE) (the Company)
hereby requests that its securities be placed into an immediate trading halt pending an
announcement in relation to finalisation of an offtake financing agreement.
The Company requests that trading in its securities be halted until after the expected
announcement is made or until the market opens on?Thursday, 7 October 2021, whichever is
the earlier.
'Offtake financing agreement' to be announced anytime before Thursday......and the chart looks good for a recovery back to the 20p + area.......
Just to say that 'Massive' is a geological term.....it does not refer to the size of the resource.......
The Kilimapesa gold mine was previously owned by Goldplat as part of its African gold portfolio but for every year of its 12 year operation it always made a loss (in 2019 it lost £1.6m!) - it's highest gold production was in 2018 (5100oz) but even then it recorded a loss to the group of £892000.
Goldplat upgraded the old processing mill through stage 1 and stage 2 upgrades but wasn't prepared to go it alone for the stage 3 upgrade and looked for outside investment. It was offloaded onto Caracal Gold (GCAT) in April 2021.....who are talking big numbers....fingers crossed it can turn Kilimapesa around........
....and 4 x 1m share trades just appeared from this morning.....big money going through this stock
Top of front page in today’s Times: https://www.thetimes.co.uk/article/switching-to-salt-substitutes-could-save-thousands-of-lives-landmark-study-shows-hzw8dtc68
Have been here years and maybe clutching at straws....but could this be the reason for the increase in share price...from today's Dhaka Tribune: https://www.dhakatribune.com/bangladesh/power-energy/2021/08/23/new-deal-with-chinese-company-likely-to-raise-coal-price-for-barapukuria-power-plant
In this article it states: 'He added that the Barapukuria Thermal Power Plant has enough coal reserves to last till January, and the current contractor would be able to ensure more coal before the reserves run out.' Perhaps Phulbari is the target for the Chinese company XMC-CMC that has an agreement to supply coal to the Barapukuria Power Plant. ..........
If you have today’s S Times then look at Money section p11…… and don’t be so f……g aggressive!
Capita is not mentioned specifically in the text which just makes general comments about the increase in numbers of takeover bids…..for the 20 companies Canaccord used its Quest valuation tool which applies ‘a leveraged buyout free cash flow yield’….. these companies don’t tend to have any debt and have cash on their balance sheets……’
Capita listed by the S Times today in a list of 20 UK companies as possible attractive takeover targets……
AZD7442 doesn't work
15 June 2021 07:00 BST
AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The trial did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 compared to placebo.
Err….. how about BP……?!
Now 6.7 to buy.......
Can't buy anything at 6.5........
2 big trades just appeared for total of £750000.....reason for taking the share price down last week?
There are so many mixed messages out there from the Gov, PHE, SAGE, etc. but my thoughts are as follows.
Covid will, over time, become less of a threat to the majority of the population - to become as successful as possible the virus wants to spread to as many people as possible and this is slowed down if the host is killed. We are seeing this with the Delta variant which, although highly transmissable, seemingly has symptoms for the majority of the UK population of the common cold....the perfect scenario for a successful virus. This brings into question the often trotted out claim by the Gov and various people in the medical profession that the vaccination policy has cut the link between infection and hospitalisation......it would seem that the Delta variant, now by far the most dominant variant in the UK, does not actually cause the symptoms of breathlessness that leads to hospitalisation....so the link has been cut not by the vaccination policy but by the virus successfully mutating to a less dangerous form.
However, there are still certain sectors of the population who are still vulnerable, ie. the elderly (who are vulnerable to any new infection), people in areas of extremely high viral lode (hospitals, etc) and those with a particular genomic sequencing that makes them naturally vulnerable to any variant. There was a particularly interesting link posted earlier today discussing the (probably accidental) release of the virus from the Wuhan lab. In broad terms those in the west have different genomic sequences to those in the east - this difference can be used to produce viruses that are only deadly to certain sectors of the world's population.....a pretty frightening thought. There is also a company out there (Oxford Biodynamics) which can very accurately predict how badly an individual would react if they are infected with a particular virus - this done through genomic sequencing through their 'EpiSwitch' blood test (only available in the US!)......so the theory seems strong.
The Government policy has been mass vaccination to protect the vulnerable - this has suited the politicians as they have been able to exercise control over a population which was becoming far too excessive in its spending habits and sense of freedom and has given the impression that the Government has delivered on an important policy and, in turn the Government will be supported by a grateful electorate (just look at the results of the local elections a couple of months ago).......it has also lead to some high value contracts being placed and appreciation in share prices of certain companies taken advantage of by those people 'in the know'.
Back to practical ideas - Synairgen could become a vital weapon against the vulnerable. Those considered vulnerable have an EpiSwitch test - if positive then suitable precautions could be taken and they could be isolated immediately if showing symptoms of the virus and treated with Synairgen as necessary.
....and now you can Buy at 53.00 and Sell at 53.11....strange indeed